Sensorion announces oral presentation at the European Histamine Research Society

May 17, 2019 05:43 UTC

Presentation of an overview of SENS-111 development

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biopharmaceutical company which specializes in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, tinnitus and vertigo, will present a keynote plenary lecture at the European Histamine Research Society in Kraków, Poland from May 15-18th, 2019.

Contrary to typically sedative H1 receptor antagonist antihistamines used in the management of vertigo, Seliforant (SENS-111) is a novel first-in-class H4 receptor antagonist.

Sensorion will cover the translational development of Seliforant starting from results of in vitro and in vivo preclinical models up until the current proof-of-concept, clinical trial stage ongoing in AUV patients (phase 2). This will include consistency between pharmacokinetic/pharmacodynamic (PK/PD) relationships predicted from preclinical models of severe vertigo and local target exposure assessment in a phase 1b clinical trial, as well as confirmed lack of sedation in the both the preclinical and clinical phase 2 setting.

The details of the oral presentation are as follows:
Session: VII Scientific Session–Biologically active compounds
Title: Translational development of Seliforant for the treatment of vertigo
Date & Time: Friday, May 17th from 12:15 PM – 12:45 PM CEST
Location: International Cultural Centre Rynek Główny 25, 31-008 Kraków

About Seliforant
Seliforant (formerly SENS-111) is the first representative candidate of the histamine type 4 receptor antagonist class to be tested for the symptomatic treatment of vertigo crises. Displaying a neuromodulation effect of the sensorineural inner ear cell function, Seliforant is a small molecule that can be taken orally or via a standard injection, and is currently in a separate Phase 2 clinical trial, being conducted in the United States, Europe, Israel and South Korea.

About Sensorion
Sensorion is a pioneering clinical-stage biopharmaceutical company, which specializes in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, vertigo and tinnitus. Our clinical-stage portfolio includes two phase 2 products: Seliforant (SENS-111) in acute unilateral vestibulopathy and Arazasetron (SENS-401) for sudden sensorineural hearing loss (SSNHL). We have built a unique R&D technology platform to expand our understanding of the pathophysiology and etiology of inner ear diseases enabling us to select the best targets and modalities for drug candidates. We also identify biomarkers to improve diagnosis and treatment of these underserved illnesses.

We are uniquely placed through our platforms and pipeline of potential therapeutics to make a lasting positive impact on hundreds of thousands of people with inner ear related disorders; a significant global unmet need in medicine today.


This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the ‘Document de référence’ registration document filed with the ‘Autorité des Marchés Financiers’ (AMF French Financial Market Authority) on September 7th, 2017 under n°R.17-062 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.


Nawal Ouzren
Tel: +33 467 207 730

Catherine Leveau
Financial communication
Tel: +33 467 207 730


Source: Sensorion

Back to news